-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Na + - glucose cotransporter 2 inhibitor can be improved with and without heart failure (HF) in diabetic patients with heart vascular outcomes
.
However, their influence on sympathetic nerve activity (SNA) is not yet clear
Diabetes, heart blood vessels
Recently, a research article was published in JAHA, an authoritative journal in the field of cardiovascular diseases.
The purpose of this study is to evaluate the effect of sodium-glucose cotransporter 2 inhibitors on SNA and compare SNA with and without HF.
The response of patients with type 2 diabetes to treatment with sodium-glucose cotransporter 2 inhibitors
.
The study included 18 patients with type 2 diabetes, 10 with HF (65.
4±3.
68 years) and 8 without HF (63.
3±3.
62 years)
.
The muscle SNA (MSNA), heart rate and blood pressure data of the subjects were recorded before and 12 weeks after the administration of dapagliflozin (5 mg/day)
Compared with non-HF patients, brain natriuretic peptide levels of HF patients increased significantly at baseline, while MSNA, blood pressure and hemoglobin A1c were not significantly different between the two groups
.
After dapagliflozin treatment, the fasting blood glucose and the insulin resistance assessed by the homeostasis model did not change significantly between the two groups
It can be seen that dapagliflozin can significantly reduce MSNA levels in patients with type 2 diabetes, regardless of its blood sugar lowering effect
.
In addition, compared with non-HF patients, the reduction of MSNA in HF patients is more significant
Dapagliflozin can significantly reduce MSNA levels in patients with type 2 diabetes, regardless of its blood sugar lowering effect
Original source:
Takuto Hamaoka.
